A novel inhalable therapy has shown promise for treating idiopathic pulmonary fibrosis (IPF) by outperforming an approved oral medicine in a mouse study. The new treatment, called VB-RT NPs, consists of lipid nanoparticles loaded with two medicines, verteporfin and berbamine, designed to disrupt both the mechanical stiffness and biochemical…
News
The naturally occurring antioxidant alpha-lipoic acid, or ALA, which protects cells against the toxic effects of iron overload, may help reduce lung damage caused by silica — dust particles often found at construction sites and in mining — in pulmonary fibrosis (PF). That’s according to a study using lab-grown…
Treatment with Endeavor Biomedicines’ experimental oral therapy taladegib (ENV-101) improved lung function in people with idiopathic pulmonary fibrosis (IPF) in a Phase 2a clinical trial, newly published results show. “IPF has devastating effects on lung function, yet patients with this disease lack effective therapeutic options. Our Phase 2a…
The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is intended to incentivize the development of treatments for rare diseases that affect fewer than 200,000 people…
Blocking caspase-9 — an enzyme involved in programmed cell death, or apoptosis — may halt or reverse tissue scarring in pulmonary fibrosis (PF), according to a new preclinical study. Researchers found elevated levels of caspase-9 in lung tissue from people with PF and in a mouse model of the…
Software that uses artificial intelligence to analyze medical imaging tests may help facilitate earlier diagnosis and more accurate monitoring of pulmonary fibrosis in people with underlying lung diseases. Brainomix‘s e-Lung could allow doctors to detect progressive pulmonary fibrosis (PPF), where lung tissue becomes increasingly scarred and leads to…
Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with idiopathic pulmonary fibrosis (IPF), according to new clinical trial data announced by the therapy’s developer, Puretech Health. Puretech has already met with the U.S. Food and Drug Administration to discuss the…
The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung disease has no known cause. The therapy will be marketed under the brand name Jascayd. According to a…
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data presented by the therapy’s developer, Boehringer Ingelheim. “The new pooled data zoom in on…
LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation and scarring in experiments done on lung tissue collected from IPF patients, according to a study. The study showed that LTI-03’s effects on inflammation and scarring were similar to those…
